Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GH Research ( (GHRS) ) just unveiled an update.
GH Research PLC reported on March 5, 2026, that it completed a successful Phase 2b trial of its inhaled mebufotenin candidate GH001 in treatment-resistant depression in 2025, demonstrating rapid and durable remission rates with a strong safety profile and short psychoactive exposure. The company is seeking U.S. FDA alignment on a global Phase 3 pivotal program, has an FDA clearance for U.S. clinical investigation of GH001, is advancing a proprietary aerosol delivery device to support pivotal trials, and ended 2025 with $280.7 million in cash and securities alongside a widened net loss driven by higher R&D and administrative spending.
For 2025, GH Research reported research and development expenses of $38.8 million and general and administrative costs of $22.0 million, contributing to a net loss of $48.3 million, or $0.79 per share, versus a $39.0 million loss a year earlier. The strengthened balance sheet and positive Phase 2b data position the company to fund its planned late-stage clinical program in TRD, potentially enhancing its standing in the emerging psychedelic-inspired depression treatment space if Phase 3 results can replicate these outcomes.
The most recent analyst rating on (GHRS) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
The score is held back primarily by weak operating fundamentals (no revenue, widening losses, and significant cash burn), partially offset by a strong, low-debt balance sheet. Technicals are moderately supportive with price above key moving averages, while valuation remains constrained due to negative earnings and no dividend data.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC is a Dublin-based clinical-stage biopharmaceutical company focused on developing novel mebufotenin-based therapies for depression, with an initial emphasis on treatment-resistant depression (TRD). Its lead candidate GH001 is delivered via a proprietary inhalation approach, while a second candidate, GH002, is formulated for intravenous administration and has completed Phase 1 testing in healthy volunteers.
Average Trading Volume: 374,743
Technical Sentiment Signal: Strong Buy
Current Market Cap: $949M
See more insights into GHRS stock on TipRanks’ Stock Analysis page.